These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

425 related items for PubMed ID: 16800840

  • 1. The impact of genotype on endocrine complications in thalassaemia major.
    Skordis N, Michaelidou M, Savva SC, Ioannou Y, Rousounides A, Kleanthous M, Skordos G, Christou S.
    Eur J Haematol; 2006 Aug; 77(2):150-6. PubMed ID: 16800840
    [Abstract] [Full Text] [Related]

  • 2. Gender differences in the prevalence and severity of bone disease in thalassaemia.
    Kyriakou A, Savva SC, Savvides I, Pangalou E, Ioannou YS, Christou S, Skordis N.
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():116-22. PubMed ID: 19337164
    [Abstract] [Full Text] [Related]

  • 3. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre.
    Gamberini MR, De Sanctis V, Gilli G.
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():158-69. PubMed ID: 19337172
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Endocrine complications in patients with Thalassaemia Major.
    Toumba M, Sergis A, Kanaris C, Skordis N.
    Pediatr Endocrinol Rev; 2007 Dec; 5(2):642-8. PubMed ID: 18084158
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Endocrinopathies, metabolic disorders, and iron overload in major and intermedia thalassemia: serum ferritin as diagnostic and predictive marker associated with liver and cardiac T2* MRI assessment.
    Chirico V, Rigoli L, Lacquaniti A, Salpietro V, Piraino B, Amorini M, Salpietro C, Arrigo T.
    Eur J Haematol; 2015 May; 94(5):404-12. PubMed ID: 25200112
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
    Wang CH, Wu KH, Tsai FJ, Peng CT, Tsai CH.
    Hemoglobin; 2006 May; 30(2):257-62. PubMed ID: 16798651
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
    Poggi M, Sorrentino F, Pugliese P, Smacchia MP, Daniele C, Equitani F, Terlizzi F, Guitarrini MR, Monti S, Maffei L, Losardo A, Pasin M, Toscano V.
    Ann Hematol; 2016 Apr; 95(5):757-63. PubMed ID: 26957357
    [Abstract] [Full Text] [Related]

  • 12. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
    Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V.
    Br J Haematol; 2010 Feb; 148(3):466-75. PubMed ID: 19912219
    [Abstract] [Full Text] [Related]

  • 13. Low bone mineral density in adolescents with beta-thalassemia.
    Vogiatzi MG, Autio KA, Mait JE, Schneider R, Lesser M, Giardina PJ.
    Ann N Y Acad Sci; 2005 Feb; 1054():462-6. PubMed ID: 16339698
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. History of myocardial iron loading is a strong risk factor for diabetes mellitus and hypogonadism in adults with β thalassemia major.
    Ang AL, Tzoulis P, Prescott E, Davis BA, Barnard M, Shah FT.
    Eur J Haematol; 2014 Mar; 92(3):229-36. PubMed ID: 24164584
    [Abstract] [Full Text] [Related]

  • 16. Osteoporosis in beta-thalassemia: Clinical and genetic aspects.
    Origa R, Fiumana E, Gamberini MR, Armari S, Mottes M, Sangalli A, Paglietti E, Galanello R, Borgna-Pignatti C.
    Ann N Y Acad Sci; 2005 Mar; 1054():451-6. PubMed ID: 16339696
    [Abstract] [Full Text] [Related]

  • 17. Glutathione S-transferase M1 gene polymorphisms are associated with cardiac iron deposition in patients with beta-thalassemia major.
    Wu KH, Chang JG, Ho YJ, Wu SF, Peng CT.
    Hemoglobin; 2006 Mar; 30(2):251-6. PubMed ID: 16798650
    [Abstract] [Full Text] [Related]

  • 18. Prevalence of diabetes mellitus in Chinese children with thalassaemia major.
    Liang Y, Bajoria R, Jiang Y, Su H, Pan H, Xia N, Chatterjee R, Lai Y.
    Trop Med Int Health; 2017 Jun; 22(6):716-724. PubMed ID: 28544032
    [Abstract] [Full Text] [Related]

  • 19. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
    Shalitin S, Carmi D, Weintrob N, Phillip M, Miskin H, Kornreich L, Zilber R, Yaniv I, Tamary H.
    Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload.
    Galanello R.
    Ann N Y Acad Sci; 2005 Feb; 1054():183-5. PubMed ID: 16339664
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.